Introduction: SLE is a chronic autoimmune rheumatic disease that is caused by autoantibodies and immune complexes for unknown reasons and causes damage to cells and organs. The aim of this study was to evaluate the association of ANA panel antibody with clinical manifestations in patients with SLE Methods: This retrospective cross-sectional study was performed on 110 patients with SLE. Clinical manifestations were evaluated according to ACR and SLICC criteria. In serum, the surface of ANA Profilling antibody was examined Results: There was no significant relationship between ANA profiling tests and disease manifestations. Except for the Anti-Ds DNA test, which was significantly associated with the clinical manifestations. (P <0.05). The results obtained from the logistic regression model show that none of these variables age, sex, malar rash, discoid, oral ulcer, nephritis and arthritis have a significant effect on the outcome Anti-U1RNP / Sm (RNP / Sm), Anti-RO- 52 recombinants, Anti-La / SS, Anti-SM not available (P > 0.05) Only age at onset has a significant effect on Anti SSA-Ro 60 (SSA) and Anti-Ds DNA tests. That is, on average, for each year of increasing the duration of the disease, the chance of a positive chance is about and about 16% increases for both tests. No significant correlation was observed with other test results at baseline. Conclusion: The present study shows an increase in the age of onset of the disease and also a decrease in the percentage of renal disorders compared to the study of the previous two decades in Iran.